Filing Details
- Accession Number:
- 0001209191-11-046264
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2011-09-01 14:15:55
- Reporting Period:
- 2011-08-31
- Filing Date:
- 2011-09-01
- Accepted Time:
- 2011-09-01 14:15:55
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
875320 | Vertex Pharmaceuticals Inc / Ma | VRTX | Pharmaceutical Preparations (2834) | 043039129 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1349077 | Lisa Kelly | C/O Vertex Pharmaceuticals Incorporated 130 Waverly St Cambridge MA 02139 | Svp, Human Resources | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2011-08-31 | 953 | $18.93 | 39,035 | No | 4 | M | Direct | |
Common Stock | Disposition | 2011-08-31 | 1,527 | $45.63 | 37,508 | No | 4 | S | Direct | |
Common Stock | Disposition | 2011-08-31 | 800 | $46.17 | 36,708 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Options | Disposition | 2011-08-31 | 953 | $0.00 | 953 | $18.93 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
953 | 2008-05-15 | 2018-05-14 | No | 4 | M | Direct |
Reported Non-Derivative Holdings
Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
---|---|---|---|
Common Stock | 1,520 | Indirect | 401(k) |
Footnotes
- Transaction made pursuant to Ms. Kelly-Croswell's company approved trading plan under Rule 10b5-1.
- Open market sales reported on this line occurred at a weighted average price of $45.63 (range $45.17 to $45.96).
- Ms. Kelly-Croswell undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- Open market sales reported on this line occurred at a weighted average price of $46.17 (range $46.00 to $46.44).
- Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 02/07/2008, except that the first quarterly vesting occurred on May 15, 2008.